< BACK AINIGMA Technologies at InnoHealth Forum 2024 Sep 24, 2024 Highlights from InnoHealth Forum 2024 iPROLEPSIS colleagues from the AINIGMA Technologies team participated in the InnoHealth Forum 2024 (20-21 September, 2024), an event that promotes and highlights innovative health technology solutions for the benefit of humanity. With 25 exhibitors, 50+ live demos of cutting-edge health products and services and over 130 matchmaking meeting and networking opportunities, this forum was a great opportunity to spread the word about the iPROLEPSIS project and connect with potential end-users. 1/5 PREVIOUS NEXT

< BACK Highlights from IFPA 2024 Jun 28, 2024 iPROLEPSIS at IFPA 2024 The 7th World Psoriasis & Psoriatic Arthritis Conference, held on June 27-29, 2024, brought together leading experts and researchers to discuss the latest advancements in psoriasis and psoriatic arthritis. Dr Laura Coates from the University of Oxford discussed the potential to prevent psoriatic arthritis, including the work being done in iPROLEPSIS and HIPPOCRATES IMI. 1/6 PREVIOUS NEXT

< BACK iPROLEPSIS at IEEE EMBC 2026 Aug 26, 2026 Representing iPROLEPSIS at an international biomedical engineering conference The 48th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (IEEE EMBC 2026) took place in Toronto, Canada, from 26 to 30 July 2026. The conference focused on “Engineering Sustainable and Equitable Healthcare” and brought together academics, medical professionals, and industry experts working in biomedical engineering and healthcare. iPROLEPSIS was represented at the conference by project partner PLUX. PLUX used the event to highlight current research initiatives and present its latest developments in biosignal measurement systems, wearable technology, and analytical software. The participation also provided opportunities for networking, exchange with specialists, and gathering feedback relevant to future development and research projects. iProlepsis_2_EMBS.jpeg iProlepsis_EMBS.jpeg iProlepsis_2_EMBS.jpeg 1/2 PREVIOUS NEXT

< BACK Hot topic debate: preventing psoriatic arthritis in patients with psoriasis Nov 13, 2024 Preventing PsA: Insights from the IFPA-WPPA 2024 Conference Conference IFPA-WPPA 2024 Conference At the 7th World Psoriasis & Psoriatic Arthritis (IFPA-WPPA) Conference , experts discussed whether effective treatment for psoriasis (PsO) could help prevent the onset of psoriatic arthritis (PsA). In this session, Prof. Laura Coates highlighted early intervention as a key strategy for PsA prevention. Supporting these efforts, the iPROLEPSIS consortium, active across Europe, is exploring digital, non-pharmacological tools aimed at improving patient outcomes. These include stress management games designed to offer additional support for people with PsO, focusing on prevention beyond medications alone. Alongside iPROLEPSIS, other studies, including the PAMPA study and HIPPOCRATES Prospective Observational Study (HPOS), are investigating early detection and intervention strategies. Digital tools such as the Psorcast app, along with new apps from iPROLEPSIS, are being developed to monitor psoriasis patients for early signs of PsA. These efforts aim to pave the way for more personalised and preventive care approaches. Abstract Can effective treatment of psoriasis (PsO) prevent the development of psoriatic arthritis (PsA)? In a Hot Topic Debate at the 7th World Psoriasis & Psoriatic Arthritis Conference, Dr. Soriano and Dr. Ogdie, both experts in the field, presented contrasting views based on existing research and clinical studies.1 Dr. Soriano argued that biologic treatments for PsO may reduce PsA risk, citing several retrospective studies. On the other hand, Dr. Ogdie argued that current observational data are plagued by biases, making it difficult to conclude whether biologics play a protective role. The session outlined the complexity of this issue, with both speakers agreeing on the need for prospective randomised controlled trials, such as the ongoing PAMPA study, to provide definitive answers. Prof. Laura Coates added that identifying at-risk patients and intervening early to potentially prevent PsA may point to a strategic research approach to address these unanswered questions. Read the full article: https://conferences.medicom-publishers.com/proceedings/proceedings-in-dermatology/7th-ifpa-wppa-conference/preventing-psoriatic-arthritis-in-patients-with-psoriasis/ 1/1 PREVIOUS NEXT

< BACK European Researchers' Night Sep 30, 2024 Engaging Communities through Science Bárbara Ramalho, Hugo Escobar, and Marta Vicente from FMH/IST-ULisboa presented the iPROLEPSIS Games and the iPROLEPSIS project at the European Researchers' Night in Oeiras, Portugal. This event, part of the "Science for Everyone (SCIEVER) – Inclusion and Sustainability" initiative, aimed to engage the public with scientific advancements. Researchers from various fields participated, sharing their work through interactive presentations, live demonstrations, and diverse activities, fostering a stronger connection between science and the community. The event unerlined the importance of making scientific research accessible to all. 1/4 PREVIOUS NEXT

< BACK Initiation of the iPROLEPSIS-PDPID Study Oct 22, 2024 Initiating Patient Enrollment for Psoriatic Arthritis Research The PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) has officially been initiated. The first patient was enrolled in the Netherlands in early September. The iPROLEPSIS-PDPID study focuses on using smart devices and clinical data to develop AI-driven models for personalised monitoring and flare prediction. This approach aims to empower patients by providing tools to better understand their condition. The study seeks to develop unobtrusive and affordable digital biomarkers capable of detecting changes in disease activity, including flares, and identifying their triggers in patients with psoriatic arthritis (PsA). The study is being conducted in four countries: the Netherlands, the UK, Portugal, and Greece. Patient recruitment is planned to start in the UK by the end of October, with recruitment in Greece and Portugal expected later this year. The miPROLEPSIS phone app is used in this study. The app is installed on patients' smartphones and acts as a data collection tool, which will be used to develop and train algorithms. The app measures physical activity, sleep duration, self-registered flares, and daily records of pain, fatigue, sleep quality, and morning stiffness. Additionally, the Garmin Vivoactive 5 smartwatch is used to collect data on physical activity, heart rate, heart rate variability, and sleep quality. 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at Healthcare & Medical Equipment Korea 2026 Apr 1, 2026 Presenting iPROLEPSIS at Korea’s leading medical technology exhibition Healthcare & Medical Equipment Korea 2026 (KIMES 2026) took place in Seoul, South Korea, from 19 to 22 March 2026. As Korea’s largest specialised exhibition for medical devices and hospital facilities, the event showcased developments in areas such as smart healthcare, AI, robotic medicine, rehabilitation, and medical information systems. iPROLEPSIS was represented at the event by project partner PLUX. The project was presented to an international audience, helping to raise its visibility in the healthcare technology field. The event also provided valuable networking opportunities and supported exchange around biosignal wearables and related digital health solutions. _09A1849.jpg 1.jpg _09A1849.jpg 1/2 PREVIOUS NEXT

< BACK iPROLEPSIS presented at MEDICA 2023 Nov 14, 2023 iPROLEPSIS project presented at the world’s largest event for the medical sector Project partners Amalia Ntemou ( Netcompany-Intrasoft ) and Georgios Apostolidis ( Aristotle University of Thessaloniki (AUTH) ) presented the iPROLEPSIS project at the MEDICA - Leading International Trade Fair in Germany. MEDICA is the world’s largest event for the medical sector. It attracts several thousand exhibitors from more than 50 countries in the halls. Furthermore, each year, leading individuals from business, research, and politics grace this top-class event with their presence. MEDICA 2023 took place on 13-16 November in Düsseldorf, Germany. IMG_20231115_135346.jpg IMG_20231115_135346.jpg 1/1 PREVIOUS NEXT

< BACK Unveiling the Future of Psoriatic Arthritis Care: Insights from Dr Laura Coates Mar 19, 2024 Exploring the iPROLEPSIS Project and Innovations in Digital Health Technologies for Enhanced Patient Care Dr Laura Coates , a researcher and clinician from the University of Oxford , guides through the research and clinical studies of the iPROLEPSIS project. In her own words: "It’s my pleasure to be leading all of the clinical studies within the iPROLEPSIS Consortium. We're focused on developing and testing apps and digital health technologies to enhance the care for patients with psoriatic arthritis ." Discover how these innovative tools aim to predict and manage psoriatic arthritis flares, identify at-risk individuals, and empower patients to take control of their health. Dr Coates elaborates on the various aspects of the research, including the development of apps that could foresee a flare, identify triggers, and even provide support for stress management and activity. https://www.youtube.com/watch?v=nYPtH0jb0yo Screenshot 2024-03-19 123331.png Screenshot 2024-03-19 123331.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Website Goes Live Mar 27, 2023 The website of the iPROLEPSIS project is finalised and available online. The website of the iPROLEPSIS project is finalised and available online. The website presents the key facts and figures about the project, and will be frequently updated about the project results, events, and key plans. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS patient survey Jun 26, 2023 iPROLEPSIS patient survey launched Have you been diagnosed with Psoriatic Arthritis ? Then we would love to get your opinion! 👉 The upcoming 4 years our European Research Team will dedicate itself to the iPROLEPSIS project. Within this project we will develop Digital Health Tools that can help you monitor your condition and can aid in the management of your Psoriatic Arthritis by providing personalised recommendations 🚀 This research was initiated by many conversations with people with Psoriatic Arthritis , who stated that the process of Trial and Error with regard to finding balance in life and gaining control over this condition is very long and complicated. We kindly ask you to complete our survey about the Digital Health Tools to be developed. This way we can design them as is important for you! 👉 The survey is available in 4 different languages available through the following links: 🔗 English: https://lnkd.in/eMhFEHMX 🔗 Greek: https://lnkd.in/en3cs-bV 🔗 Portuguese: https://lnkd.in/dy76S8Rg 🔗 Dutch: https://lnkd.in/ecTgfJh9 Your participation and feedback are valuable to us 👋 Together, we can shape the future of Psoriatic Arthritis management! For further information or if you have any questions, please visit: 🌐 Website: www.iprolepsis.eu 👍 LinkedIn: https://lnkd.in/dnrTP8rC 🐦 Twitter: https://twitter.com/iprolepsis Thank you in advance for contributing your opinion. Your voice matters! News & Events iPROLEPSIS - events.png News & Events iPROLEPSIS - events.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Games Presented at HiTech Program in Lisbon Jun 27, 2025 FMH/IST-ULisboa team showcased the project’s serious games to investors and health innovation experts On June 26, 2025, the iPROLEPSIS Games were presented during the final pitch session of the HiTech Program , held at the Thalia Theater in Lisbon, Portugal. Representing FMH/IST-ULisboa , Samuel Gomes , Bárbara Ramalho , and Filipa Magalhães introduced the iPROLEPSIS Games to an audience of investors and stakeholders interested in supporting innovative health solutions. This opportunity marked an important step in sharing iPROLEPSIS tools with a wider innovation and investment community. Read more about HiTech program here: https://hiseedtech.com/programs#header HiTech.jpg HiTech.jpg 1/1 PREVIOUS NEXT